Lpath, Inc. - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 32 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Lpath, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Lpath, Inc. - Product Pipeline Review - 2014', provides an overview of the Lpath, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Lpath, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Lpath, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Lpath, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Lpath, Inc.'s pipeline products

Reasons to buy

- Evaluate Lpath, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Lpath, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Lpath, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Lpath, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lpath, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Lpath, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Lpath, Inc. Snapshot 4
Lpath, Inc. Overview 4
Key Information 4
Key Facts 4
Lpath, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Lpath, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Lpath, Inc. - Pipeline Products Glance 10
Lpath, Inc. - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Lpath, Inc. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
Lpath, Inc. - Drug Profiles 13
LT-1009 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Lpathomab 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Nextomabs 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Lpath, Inc. - Pipeline Analysis 19
Lpath, Inc. - Pipeline Products by Target 19
Lpath, Inc. - Pipeline Products by Route of Administration 20
Lpath, Inc. - Pipeline Products by Molecule Type 21
Lpath, Inc. - Pipeline Products by Mechanism of Action 22
Lpath, Inc. - Recent Pipeline Updates 23
Lpath, Inc. - Dormant Projects 26
Lpath, Inc. - Company Statement 27
Lpath, Inc. - Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 32
Disclaimer 32

List of Tables
Lpath, Inc., Key Information 4
Lpath, Inc., Key Facts 4
Lpath, Inc. - Pipeline by Indication, 2014 7
Lpath, Inc. - Pipeline by Stage of Development, 2014 8
Lpath, Inc. - Monotherapy Products in Pipeline, 2014 9
Lpath, Inc. - Phase II, 2014 10
Lpath, Inc. - Preclinical, 2014 11
Lpath, Inc. - Discovery, 2014 12
Lpath, Inc. - Pipeline by Target, 2014 19
Lpath, Inc. - Pipeline by Route of Administration, 2014 20
Lpath, Inc. - Pipeline by Molecule Type, 2014 21
Lpath, Inc. - Pipeline Products by Mechanism of Action, 2014 22
Lpath, Inc. - Recent Pipeline Updates, 2014 23
Lpath, Inc. - Dormant Developmental Projects,2014 26
Lpath, Inc., Subsidiaries 30